Review
Copyright ©The Author(s) 2016.
World J Gastroenterol. Sep 21, 2016; 22(35): 7868-7881
Published online Sep 21, 2016. doi: 10.3748/wjg.v22.i35.7868
Table 1 Clinical impact of obesity on inflammatory bowel disease
Medical therapySurgical therapyNatural history and disease complications
Decreased clinical response to azathioprine[77]Earlier time to 1st surgery[15]Conflicting data:
Lower 6-thioguanine levels on treatment with azathioprine[78]Higher rate of perioperative complications[112,114,119-121]Higher prevalence of perianal disease[22]
Decrease likelihood of response to adalimumab[83]Increased need for conversion from laparoscopic to open surgery[113,118]Lower prevalence of penetrating disease[24]
Shorter time to loss of response to infliximab[92]Increased hospitalization[22]
Decreased IBD-related quality of life[23]
Decreased healthcare utilization[14]
Table 2 Immunologic effect of adipokines
AdipokineLevels in obesityImmunologic effectsOverall effect
AdiponectinDecreasedDecreases TNF-α, IFNγ, IL-6Anti-inflammatory
Inhibits VCAM-1, ICAM-1 expression
Increases IL-10, IL-1RA
Promotes proliferation of Tregs
Antagonizes NF-κB pathway
LeptinIncreasedIncreased activation and proliferation of monocytes and macrophagesPro-inflammatory
Increased IL-6, TNF-α, IL-12
Activates NK cells
Activates NF-κB pathway
Promotes Th1-differentiation
Inhibits proliferation of
Tregs
ResistinIncreasedIncreases IL-6, IL-12, TNF-αPro-inflammatory